Trial Profile
Long term efficacy and safety in children and young adults with treatment resistant epilepsy treated with Cannabidiol
Status:
Recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 23 Dec 2022
Price :
$35
*
At a glance
- Drugs Cannabidiol (Primary)
- Indications Epilepsy; Seizures
- Focus Adverse reactions; Expanded access; Therapeutic Use
- 20 Dec 2022 Results(4-year results) assessing Long-term efficacy and safety of cannabidiol in patients with treatment-resistant epilepsies through January 2019 published in the Epilepsia
- 22 Apr 2021 Results Evaluating the effect of CBD on convulsive (clonic, tonic, tonic-clonic, atonic, focal to bilateral tonic-clonic) and nonconvulsive (focal, absence, myoclonic, myoclonic-absence, spasms) seizures and safety in patients with TREs in the EAP presented at the 73rd Annual Meeting of the American Academy of Neurology
- 13 Apr 2021 According to a GW Pharmaceuticals media release, results of this trial will be presented at the 2021 American Academy of Neurology.